Prevalence estimates have been produced by a two-step approach:
1. A comprehensive systematic review of the literature on the prevalence of psoriasis.
2. A meta-analysis which has used an advanced statistical model to generate estimates for every country, region and super-region of the world.
For further details about how the prevalence data is calculated, please click on https://www.bmj.com/content/369/bmj.m1590
Not all countries have available data on the prevalence of psoriasis, therefore for some countries the estimates have a high level of uncertainty and need to be interpreted with caution.
The website reports the crude prevalence estimates. (These have not been age-and-gender standardised due to lack of information).
The website reports the crude prevalence estimates. (These have not been age-and-gender standardised due to lack of information). Therefore, comparison between countries, particularly between countries with very different population age structure, need to be interpreted with caution.
A detailed academic publication will be available soon for reference. For more information please contact the GPA team.
INTERPRETATION OF THE ESTIMATES OF THE PREVALENCE OF PSORIASIS
HOW PREVALENCE ESTIMATES HAVE BEEN CALCULATED?
An extensive search of all available evidence was conducted and all the published articles on the prevalence of psoriasis were identified. All the information reported was assessed and used them to inform a statistical model. The statistical model generated a pooled estimate of the prevalence of psoriasis for each individual country where data were identified. Each prevalence measure is presented together with a range (uncertainty interval) which represents the uncertainty surrounding the estimate. Therefore, these values are not to be interpreted as exact measures, but only as measures which can vary within a certain range.
COUNTRIES WITH MISSING DATA
To be noted, many countries of the world do not provide information on the prevalence of psoriasis. For these countries, without high quality original data sources, estimates were generated by extrapolation, making using of the psoriasis prevalence estimate of the region the country was nested in, grouped according to the United Nations classification. Therefore, extrapolated estimated are less reliable, than for countries with original data sources and should be interpreted with caution. Please note, a publication will be available soon where all the countries with extrapolated estimates will be listed in a Table.
Refers to all adult population.
A rate for a specified age group (adults or children), in which the numerator and denominator refers to the same age group.
A statistical technique that facilitates comparison of prevalence rates between populations or overtime, adjusting for differences in the age structure of the general population in the countries or regions being compared.
Refers to all children and adolescents individuals.
Prevalence data are presented for 196 countries of the world *. Countries are nested into regions which are nested into super-regions.
The process of identifying a disease by its signs and symptoms. The diagnosis of psoriasis can be made either by a general practitioner/ physician or by a dermatologist.
The number of new cases arising in a given period in a specified population. This information can be expressed as an absolute number of cases per year or as a rate per 100,000 persons per year.
A statistical analysis that combines the results of multiple studies addressing the same question with the aim of deriving a pooled estimate closest to the unknown common truth.
Refers to all individuals of any age, therefore children and adults combined.
The existing number of persons in a defined population who have been diagnosed with psoriasis. It is usually expressed as a proportion and can assume different definitions according to how it is measured. Therefore, it can be classified into: point, period and lifetime prevalence. Point prevalence: when the number of cases refers to a specific time point (e.g. a year). Period prevalence: when the number of cases refers to a time-window (e.g. between 2000 and 2010). Lifetime prevalence: when it refers to the entire previous life of an individual (e.g. “Have you ever been diagnosed with psoriasis?”).
Prevalence data are presented for 21 regions of the world (which contain 196 countries) *. Regions are nested into super-regions.
Prevalence data are presented for 7 super-regions of the world (which contain 21 regions in which are nested 196 countries) *.
UNCERTAINTY INTERVALS/CREDIBLE INTERVALS
Uncertainty intervals have been produced by the statistical models to quantify the uncertainty around prevalence estimates. These intervals thus reflect the uncertainty levels around the psoriasis prevalence estimates.
*according to the definition of the United Nation - https://population.un.org